← Back to Search

Hyperpolarized Helium MRI for COPD Tracking

N/A
Recruiting
Led By Grace E Parraga, PhD
Research Sponsored by Dr. Grace Parraga
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject is ambulatory and can perform the 6MWT
Subject must be able to perform a breathhold for 16s
Must not have
Patient is unable to perform spirometry or plethysmography maneuvers
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is to develop imaging tools to track COPD and Bronchiectasis patients over time.

Who is the study for?
This trial is for men and women aged 50-85 with COPD, Bronchiectasis, or a significant smoking history (≥10 pack/years). Participants must be able to hold their breath for 16 seconds, walk on their own, perform specific lung function tests successfully, and have certain levels of lung capacity. Pregnant individuals or those with metal implants that can't be removed are excluded.
What is being tested?
The study involves using advanced MRI techniques with Helium-3 and Xenon-129 to image the lungs. It aims to develop tools for better understanding the changes in the lungs over time due to COPD or Bronchiectasis by comparing CT scans and MRIs.
What are the potential side effects?
While not explicitly listed in the provided information, typical side effects from MRI procedures may include discomfort from lying still during imaging, loud noises during scanning which might require ear protection, and potential feelings of claustrophobia.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can walk on my own and can do a 6-minute walk test.
Select...
I can hold my breath for 16 seconds.
Select...
I am between 50-85 years old and have COPD, Bronchiectasis, or a smoking history of more than 10 pack-years.
Select...
I can perform consistent lung function tests.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot perform certain lung function tests.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Apparent Diffusion Coefficients (ADC)
Ventilation Defect Percent (VDP)
Secondary study objectives
Six Minute Walk Distance (6MWD)
Spirometry
St. George's Respiratory Questionnaire (SGRQ)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: COPD and Bronchiectasis PatientsExperimental Treatment1 Intervention
All enrolled COPD and Bronchiectasis patients will undergo Pulmonary Function Tests, Hyperpolarized Helium MRI, chest CT, 6-Minute Walk Test, and complete questionnaires at up to 8 visits over 2-3 years.

Find a Location

Who is running the clinical trial?

Dr. Grace ParragaLead Sponsor
5 Previous Clinical Trials
285 Total Patients Enrolled
London Health Sciences CentreOTHER
146 Previous Clinical Trials
52,154 Total Patients Enrolled
1 Trials studying Bronchiectasis
32 Patients Enrolled for Bronchiectasis
Grace E Parraga, PhDPrincipal InvestigatorRobarts Research Institute, The University of Western Ontario
14 Previous Clinical Trials
1,164 Total Patients Enrolled
1 Trials studying Bronchiectasis
32 Patients Enrolled for Bronchiectasis

Media Library

COPD and Bronchiectasis Patients Clinical Trial Eligibility Overview. Trial Name: NCT02279329 — N/A
Bronchiectasis Research Study Groups: COPD and Bronchiectasis Patients
Bronchiectasis Clinical Trial 2023: COPD and Bronchiectasis Patients Highlights & Side Effects. Trial Name: NCT02279329 — N/A
COPD and Bronchiectasis Patients 2023 Treatment Timeline for Medical Study. Trial Name: NCT02279329 — N/A
~2 spots leftby Feb 2025